UI Hospitals and Clinics

Studies | Researchers

Clinical Research

Showing newest first. Show oldest first. Or order by title

  1. A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, p…
    David Bushnell
  2. Medamacs: The Medical Arm of Mechanical Circulatory Support
    Linda Cadaret
  3. Real-World Driving Safety in OSA
    Matthew Rizzo
  4. A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
    David Bender
  5. Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymp…
    Ayman El-Sheikh
  6. Transfusion of Prematures (TOP) Trial
    Edward F. Bell
  7. A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND #74019, NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
    David Bender
  8. A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexat…
    Ayman El-Sheikh
  9. Cognitive and Psychiatric Functioning in Adults with Carcinoid Tumors
    Megan Smith
  10. Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer
    Daniel Vaena
  11. Randomized Phase II Study Comparing the MET inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
    Mohammed Milhem
  12. Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc P(1)
    Brian Link
  13. GOG 3001/ Amgen TRINOVA-3 - A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III…
    David Bender
  14. Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
    Ayman El-Sheikh
  15. A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) vs. Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma
    David Bender
  16. A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Rel…
    Brian Link
  17. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects…
    Brian Link
  18. A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresecta…
    Mohammed Milhem
  19. Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Pa(1)
    Daniel Vaena
  20. Randomized, double-blind phase III study of Pazopanib vs Placebo in subjects with metastatic renal cell carcinoma who have no evidence of disease following metastatectomy
    Daniel Vaena

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.